아시아태평양의 임상 바이오마커 시장 : 분석 및 예측(2023-2033년)

Introduction to Asia-Pacific Clinical Biomarkers Market

The Asia-Pacific clinical biomarkers market was valued at $3.28 billion in 2023 and is expected to reach $7.95 billion by 2033, growing at a CAGR of 9.27% between 2023 and 2033. Clinical biomarkers are quantifiable biological parameters that aid in understanding the progression and early diagnosis of diseases. These biomarkers, particularly molecular ones, offer new targets for characterizing diseases and for drug discovery and development.

Market Introduction

The Asia-Pacific (APAC) clinical biomarkers market is rapidly expanding, driven by advancements in biotechnology, increased healthcare spending, and a growing focus on personalized medicine. Countries like China, Japan, and India are at the forefront, with substantial investments in research and development and robust clinical trial activities. The rising prevalence of chronic diseases, such as cancer and cardiovascular conditions, fuels the demand for early diagnostic tools and targeted therapies. Government initiatives and collaborations between academic institutions and biopharmaceutical companies further propel market growth. The integration of advanced technologies, such as next-generation sequencing and bioinformatics, enhances the identification and validation of novel biomarkers, making the APAC region a crucial player in the clinical biomarkers landscape.

Market Segmentation:

Segmentation 1: by Country

• China
• India
• Japan
• South Korea
• Australia
• Rest-of-Asia-Pacific

How Can This Report Add Value to an Organization?

Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.

Competitive Strategy: The clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Asia-Pacific clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are

• BGI
• Novogene Co., Ltd.

Table of Contents

Executive Summary

1 Market

2 Market Scope

• 2.1 Key Questions Answered in the Report

3 Research Methodology

• 3.1 Data Sources
  • 3.1.1 Primary Data Source
  • 3.1.2 Secondary Data Sources
    • 3.1.2.1 Open Sources
• 3.2 Market Estimation Model
• 3.3 Criteria for Company Profiling

4 Market Overview

• 4.1 Introduction
• 4.2 Clinical Biomarkers Approaches in Precision Medicine
• 4.3 Market Size Potential for Clinical Biomarkers, 2022-2033
• 4.4 COVID-19 Impact on Clinical Biomarkers Market
  • 4.4.1 COVID-19 Impact on Market Size
• 4.5 Market Trends
  • 4.5.1 Integration of Artificial Intelligence in Biomarker Discovery
  • 4.5.2 Increasing Biomarkers Usage in Precision Medicine
  • 4.5.3 Technologies Being Used in Clinical Biomarker Testing
  • 4.5.4 Clinical Biomarker Discovery Making Early Disease Diagnosis Possible

5 Region

• 5.1 Overview
• 5.2 Asia-Pacific
  • 5.2.1 China
  • 5.2.2 India
  • 5.2.3 Japan
  • 5.2.4 South Korea
  • 5.2.5 Australia
  • 5.2.6 Rest-of-Asia-Pacific

6 Market - Company Profiles

• 6.1 Overview
• 6.2 BGI
  • 6.2.1 Company Overview
  • 6.2.2 Role of BGI in the Clinical Biomarkers Market
  • 6.2.3 Corporate Strategies
    • 6.2.3.1 Product Launch
  • 6.2.4 Analyst's Perspective
• 6.3 Novogene Co., Ltd.
  • 6.3.1 Company Overview
  • 6.3.2 Role of Novogene Co., Ltd. in the Clinical Biomarkers Market
  • 6.3.3 Analyst's Perspective